Contact

Investment analysis in regenerative medicine. Histocell and Cell Innovation Partners


, , ,
Integral service around a transaction
BY : Diego GutiérrezOctober Fri, 2018

We analyse the case of Histocell, a biopharmaceutical company focused on the development of drugs and medical devices for regenerative medicine and cell therapy, from a corporate finance perspective. Firstly, we will explain the strategic rationale through the inauguration of its new production centre. Then, we will highlight the capital investment Histocell has received thanks to the Japanese investment fund Cell Innovation Partners, an operation that has made the opening of its new plant possible.

Get in touch with our experts.

We analyse the case of Histocell, a biopharmaceutical company focused on the development of drugs and medical devices for regenerative medicine and cell therapy, from a corporate finance perspective. Firstly, we will explain the strategic rationale through the inauguration of its new production centre. Then, we will highlight the capital investment Histocell has received thanks to the Japanese investment fund Cell Innovation Partners, an operation that has made the opening of its new plant possible.

Histocell inaugurates a plant dedicated to the manufacture of medical devices

The Basque biopharmaceutical company Histocell opened a new production centre in Larrabetzu dedicated to the manufacture of medical products for regenerative medicine.

Hostocell belongs to the NorayBio Group. This group was created in 2006 with the aim of bringing together innovative Basque biotech companies with an international vocation. The group, founded by Julio Font and Marta Acilu, currently includes three companies in the bioscience area located in the Science and Technology Park of Bizkaia: Noray Bioinformatics, Histocell and ArtinVet.

Histocell is a biopharmaceutical company that develops cell therapy and tissue engineering products for regenerative medicine. Histocell began its trajectory in the Department of Cell Biology and Histology of the Faculty of Medicine and Odontology of the University of the Basque Country, to later set up in 2005 in the Science and Technology Park of Bizkaia. However, the aim of this new centre is to house research, production and marketing activities for its Reoxcare line of treatment for difficult-to-heal wounds and its Wharton Gel Complex and Histoessence dermocosmetic products.

In short, the creation of this plant has involved an investment of €1.6m and will generate 10 jobs at the start of its operation and, it is expected, around 30 in the coming years. With all this, the company forecasts sales of €6m by 2021.

CORPORATE FINANCE EXPERTS

Capital increase for the start-up of the new production site thanks to the Japanese investment fund Cell Innovation Partners.

La inauguración no es el único hito empresarial alcanzado por Histocell este año. Asimismo, la compañía ha realizado una capital increase para la apertura de su nueva planta en la que se ha dado entrada al fondo de inversión japonés Cell Innovation Partners. Dicho fondo guarda relación con la actividad de Histocell, pues también está especializado en medicina regenerativa y terapia celular. Los principales socios de dicho fondo son la empresa japonesa Reprocell y el banco Shinsei.

On the one hand, Reprocell was founded in 2003 by Japanese university researchers. Later, it became the leading stem cell research company in Japan. In recent years, it expanded through a series of acquisitions to become REPROCELL Group Companies. In this way, each acquired company brings intellectual property and knowledge that helps amplify the value of the organisation. More recently, these companies have been integrated and consolidated into regional offices, and the names have become product and service brands.

On the other hand, Shinsei Banka Japanese financial institution offering a full range of financial products and services for institutional and individual clients. Shinsei combines its commercial and investment banking operations - with frequent investments in Europe - with an Institutional Banking division that engages in a wide range of commercial lending and equity investments. This division is affiliated with four subsidiary companies: Shinsei Investment Management, Shinsei Securities, Shinsei Servicer and Shinsei Trust and Banking.

Finally, Histocell has obtained the necessary investment to start up its new production centre in Larrabetzu, in which its partners and some institutional bodies such as the Provincial Council of Bizkaia and the Basque Government's Gauzatu programme, dedicated to promoting the creation and development of technology-based and innovative SMEs, have also participated.

Analysis of similar operations in the field of regenerative medicine

The following table lists five international operations related to regenerative medicine. For example, Humacyte offers human tissue-based products for regenerative medicine and vascular surgery applications. The company, which was incorporated in 2004 and is based in North Carolina, has received 467.9M$.

CompanyCountryDescription Total amount of investmentDate of the last round
DialpadUnited StatesDialpad offers simplified cloud-based business phone solutions for every business.$120M17/07/2018
WiseUnited KingdomSabio is a unified communications and contact centre services company.£50M11/07/2016
AircallFranceAircall is an advanced call centre, full business phone and contact centre software natively integrated into any CRM.$40,6M15/05/2018
3CLogicUnited States3CLogic provides cloud-based multi-channel communications for helpdesk and sales organisations.$11,5M22/08/2016

Other posts that may interest you

Investment analysis in the Dental Tech.Createch Medical and Straumann sectors.

Analysis of health equity investment

Nokia buys health gadget company Withings and enters E-health world

Yes looking for investors, you want to buy or sell your company or finance your R&D&I project, get in touch with our Corporate Finance experts.

If you are looking for investors, want to buy or sell your company or finance your R&D&I project, contact our Corporate Finance experts.

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu